

11245/53202

U.S. APPLICATION NO. (If known - see 37 CFR 1.5)
To Be Assigned

107555407

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED:
PCT/US2004/013852	03 May 2004	01 May 2003

TITLE OF INVENTION

FULLY HUMAN ANTIBODIES DIRECTED AGAINST THE HUMAN INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR

APPLICANT(S) FOR DO/EO/US

Dale L. LUDWIG

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. The US has been elected (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto.
 - b. has been previously submitted under 35 U.S.C. 154(d)(4).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (Unsigned)
10. An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. Preliminary Amendment.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. An Application Data Sheet under 37 CFR 1.76.
15. A substitute specification.
16. A power of attorney and/or change of address letter.
17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.
18. A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. Other items or information: Copy of Published International Application; copy of International Search Report; Sequence Listing in paper form (eighteen(18) pages) and computer readable form (one(1) diskette); Sequence Listing Statement

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) To Be Assigned 104555407		INTERNATIONAL APPLICATION NO. PCT/US2004/013852	ATTORNEY'S DOCKET NUMBER 11245/53202
The following fees are submitted:			
21 <input type="checkbox"/> Basic National Fee		\$ 300.00	\$300.00
22. <input type="checkbox"/> Examination Fee – If International preliminary exam report prepared by USPTO and all claims satisfy provisions of PCT Article 33/(1)-(4).....		\$ 100.00	\$
<input type="checkbox"/> Examination Fee - All other situations		\$ 200.00	\$200.00
23. <input type="checkbox"/> Search Fee – Search fee (37 CFR 1.445(a)(2) has been paid on the international application to the USPTO as ISA		\$ 100.00	\$
<input type="checkbox"/> International Search Report prepared and provided to the Office.....		\$ 400.00	\$400.00
<input type="checkbox"/> Search Fee – All other situations		\$ 500.00	\$
TOTAL OF ABOVE CALCULATIONS			\$900.00
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing on computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.			
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE
-100	/50=	1	x \$250
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).			
CLAIMS		NUMBER FILED	NUMBER EXTRA
Total Claims		73 - 20 = 53	x \$50.00 2,650.00
Independent Claims		5 - 3 = 2	x \$200.00 \$400.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$360.00 \$360.00
TOTAL OF ABOVE CALCULATIONS =			\$
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.			
SUBTOTAL = \$4,310.00			
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			
TOTAL NATIONAL FEE = \$4,310.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property			
TOTAL FEES ENCLOSED = \$4,310.00			
		Amount to be refunded:	\$
		Amount to be charged	\$
a. <input type="checkbox"/>	A check in the amount of \$ _____ to cover the above fees is enclosed.		
b. <input checked="" type="checkbox"/>	Please charge my Deposit Account No. <u>11-0600</u> in the amount of \$4,310.00 to cover the above fees. A duplicate copy of this sheet is enclosed.		
c. <input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>11-0600</u> . A duplicate copy of this sheet is enclosed.		
d. <input type="checkbox"/>	Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO: KENYON & KENYON One Broadway New York, New York 10004 CUSTOMER NO. 26646			
		SIGNATURE Lawrence P. Casson (Reg. No. 46,606)	
		NAME <u>Lawrence P. Casson</u>	
		DATE <u>November 1, 2005</u>	